13-CIS-RETINOIC ACID PLUS INTERFERON-ALPHA: ACTIVE SYSTEMIC THERAPY FOR ADVANCED SQUAMOUS CELL CARCINOMA OF THE CERVIX (MEETING ABSTRACT)

Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

13-CIS-RETINOIC ACID PLUS INTERFERON-ALPHA: ACTIVE SYSTEMIC THERAPY FOR ADVANCED SQUAMOUS CELL CARCINOMA OF THE CERVIX (MEETING ABSTRACT)

Proc Annu Meet Am Soc Clin Oncol; 11:A709 1992. Unique Identifier : AIDSLINE ICDB/92681438
Kavanagh J; Lippman S; Paredes M; Kudelka A; Paredes P; Delgadillo F; Silva E; Holdener E; Hong W; Wharton JT; et al; UT M.D. Anderson Cancer Center, Houston, TX 77030

Abstract: A Phase II trial of 13-cis-retinoic acid (13-cRA) plus recombinant interferon-alpha (IFN-alpha 2A) was conducted in advanced untreated squamous cell carcinoma of the cervix. 13-cRA was given po at 1 mg/kg daily and IFN-alpha 2A sc at 6 x 10(6) U/day. Patients (pts) were examined monthly by two physicians for determination of response. Informed consent was obtained from all pts. All pts are HIV negative. All 32 enrolled pts are evaluable for response and toxicity. Stage II or greater disease was present in 24 (75%) pts. Major responses (greater than or equal to 50% tumor reduction) occurred in 47% (15/32), of which 9% (3/32) were complete. Two pts had histologic complete remission at hysterectomy. Of the 15 responders, 7 progressed on therapy. Responses occurred in 50% (7/14) of pts with Stage IIIB-IV disease. Response rates were 66% (10/18) in large (greater than or equal to 10 cm) primary lesions and 56% (9/16) in poorly differentiated tumors. Major symptomatic relief correlated with response. Adherence was 100% and toxicity was minimal. Dose reduction has been required in only 1 pt due to grade III toxicity of fatigue. Sequential studies for nuclear retinoic acid receptors, growth factor receptors and HPV analysis are in progress. The combination of 13-cRA acid and INF-alpha 2A is well tolerated and has major activity in advanced untreated squamous cell carcinoma of the cervix. Future work should concentrate on combinations of this study regimen with chemotherapy, radiotherapy, and as an adjuvant modality.

Keywords: Carcinoma, Squamous Cell/PATHOLOGY/*THERAPY Cervix Neoplasms/PATHOLOGY/*THERAPY Female Human Interferon Alfa-2a/ADVERSE EFFECTS/*THERAPEUTIC USE Neoplasm Staging Treatment Outcome Tretinoin/ADVERSE EFFECTS/*THERAPEUTIC USE ABSTRACT
920930
M9290911

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .